Figure 5.

Efficacy outcomes in the Japanese cohort from CHRONOS, including (a) the proportion of patients achieving Investigator's Global Assessment (IGA) 0 or 1 at weeks 16 and 52 and with ≥ 2‐point improvement from baseline and (b) the proportions of patients achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at weeks 16 and 52. Values in white font denote patient numbers (n/N). Values after the first rescue treatment used were set to missing (censoring). Patients with missing IGA or EASI scores at each visit were considered nonresponders. Statistical analyses at week 16 were based on the primary analysis dataset. qw, weekly; q2w, every 2 weeks; TCS, topical corticosteroids.